Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
Summary
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Official title: Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
404
Start Date
2022-07-19
Completion Date
2027-05-19
Last Updated
2024-02-22
Healthy Volunteers
No
Interventions
Erenumab 140 Mg/mL Subcutaneous Solution
Active erenumab delivered via subcutaneous injection.
Placebo
Placebo delivered via subcutaneous injection.
Locations (4)
Womack Army Medical Center - Fort Liberty
Fort Bragg, North Carolina, United States
University of Pittsburgh Concussion Research Laboratory
Pittsburgh, Pennsylvania, United States
William Beaumont Army Medical Center
El Paso, Texas, United States
Madigan Army Medical Center
Tacoma, Washington, United States